Today: 21 May 2026
Browse Category

NYSE:PFE 6 February 2026 - 17 May 2026

Pfizer Faces Busy Week After Friday’s Drop

Pfizer Faces Busy Week After Friday’s Drop

Pfizer shares closed at $25.33 Friday, down 1.63%, underperforming the S&P 500, which fell 1.24% but still posted a weekly gain. The company reaffirmed its 2026 revenue and earnings guidance after first-quarter revenue rose 5% to $14.45 billion. Investors remain cautious, citing competitive pressure from Eli Lilly and uncertainty over Pfizer’s pipeline. U.S. markets reopen Monday.
17 May 2026
···
Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc Looks to India, but Investors Hold Off

Pfizer is increasing investment in India for cancer drugs, obesity treatments, and vaccines as it seeks growth beyond COVID-era sales. The company reported Q1 revenue of $14.5 billion, up 5%, but expects a $1.5 billion hit this year from generic competition. Shares fell 1.8% to $25.29 in New York trading. In Europe, Pfizer won expanded approval for its hemophilia drug Hympavzi.
15 May 2026
·
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

A Delaware federal judge dismissed Acuitas Therapeutics’ attempt to clear Pfizer and BioNTech’s Comirnaty vaccine from GSK patent claims, citing lack of jurisdiction. The ruling does not address whether Comirnaty infringes GSK’s patents. Pfizer shares last closed at $25.68, down 1.42%. The company reaffirmed 2026 revenue guidance and reported first-quarter revenue of $14.5 billion.
11 May 2026
··
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax shares jumped 13% Friday after first-quarter revenue reached $139.5 million, beating estimates. Licensing and partner payments, including $30 million from Pfizer’s Matrix-M deal, offset weak COVID-19 vaccine demand. The stock traded at $10.45 with volume over 8.4 million shares. Investors await the company’s appearance at BofA’s health-care conference on May 13.
8 May 2026
···
Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer posted first-quarter adjusted earnings of 75 cents per share on $14.45 billion in revenue, beating Wall Street forecasts. Sales of Eliquis and Padcev rose, offsetting steep declines in COVID products. The company maintained its 2026 revenue and profit outlook. Research and development expenses increased 12% as Pfizer invested in oncology and obesity drugs.
5 May 2026
···
Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

The FDA granted priority review to Pfizer and Astellas’ Padcev for muscle-invasive bladder cancer, setting an Aug. 17 decision date. Pfizer shares rose 0.8% to $27.78 after the news. The company reports first-quarter results May 5, with investors watching oncology and obesity drugs to offset declining COVID sales and loss of exclusivity on older products.
20 April 2026
··
Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners sold a combined 740,174 Pfizer shares in the fourth quarter, according to recent 13F filings. Pfizer stock traded down 0.7% at $28.12 Monday. The three firms still held about $140.9 million in Pfizer shares at year-end. Pfizer halted a major U.S. COVID shot study after the period covered by the filings.
6 April 2026
··
Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer shares hit a 52-week high of $28.30 in New York Tuesday, lifted by recent drug pipeline updates and strong fourth-quarter sales. The company reported Q4 revenue of $17.56 billion and reaffirmed 2026 guidance. Some analysts remain cautious, with Acquirer’s Multiple valuing shares at $14–$15. Recent trial data showed positive results for Talzenna in prostate cancer and atirmociclib in breast cancer.
31 March 2026
··
Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer shares closed down 1% at $26.60 Friday after GSK’s RSV vaccine won expanded FDA approval for at-risk adults 18 to 49, narrowing Pfizer’s lead in the RSV market. Positive trial data for Pfizer’s blood thinner Eliquis offset some pressure, but the stock finished near session lows amid broader market weakness and uncertainty over the company’s near-term growth outlook.
13 March 2026
···
Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer shares fell 1.6% to $26.86 Thursday amid a broad U.S. market selloff as oil prices rose on Middle East tensions. The company faces pressure from declining COVID product sales and forecast 2026 profit below Wall Street estimates. China approved Pfizer’s GLP-1 weight-loss drug last week, while rival Eli Lilly announced a $3 billion China investment. Pfizer lost a legal bid in generic-drug litigation this week.
12 March 2026
···
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer shares rose 2.7% to $27.22 Friday after the FDA granted Priority Review to its hemophilia drug HYMPAVZI, with a decision expected by mid-2026. Trading volume reached 30 million shares. The company also launched the TrumpRx discount program, offering cash discounts on over 30 drugs. The White House said TrumpRx.gov debuted Thursday with “most-favored nation” pricing on 40 branded drugs.
6 February 2026
···
Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer shares fell 1.1% to $26.49 in premarket trading after the TrumpRx discount drug portal launched Thursday, raising concerns over U.S. drug pricing. Pfizer said its TrumpRx program offers discounts of up to 85% on more than 30 medicines. The FDA granted Priority Review for expanding Hympavzi use in younger hemophilia patients, with a decision expected in the second quarter.
6 February 2026
··
1 2 3 … 10

Stock Market Today

  • U.S. Stocks Rise Sharply on Iran Deal Optimism and Oil Price Drop
    May 21, 2026, 5:05 AM EDT. U.S. stock indexes surged on Wednesday led by the S&P 500 (+1.08%), Dow Jones (+1.31%), and Nasdaq 100 (+1.66%), driven by a sharp decline in crude oil prices of over 5% amid hopes for an Iran war resolution. Lower oil prices eased inflation expectations and caused the 10-year Treasury yield to drop 10 basis points to 4.57%. Semiconductor shares advanced, with Nvidia rising over 1% ahead of earnings expected to show strong AI-related sales growth. Federal Reserve minutes indicated a hawkish stance with many policymakers supporting potential rate hikes if inflation remains above 2%. The market anticipates a low chance (7%) of an interest rate cut at the upcoming FOMC meeting on June 16-17. Mortgage applications declined, and the 30-year fixed mortgage rate increased to 6.56%.

Latest articles

Arm Stock Shock: AI Chip Bet Sends Shares Toward New Highs Before Nasdaq Open

Arm Stock Shock: AI Chip Bet Sends Shares Toward New Highs Before Nasdaq Open

21 May 2026
Arm Holdings shares closed Wednesday at $256.73, up 15.05%, after Bernstein’s David Dai initiated coverage with an outperform rating and a $300 target, citing rising demand for server CPUs driven by agentic AI. The stock touched $259.44 during regular trading. U.S. markets were open; May 21 is not a listed exchange holiday. Arm’s AGI CPU has over $2 billion in expected demand for fiscal 2027 and 2028.
T1 Energy Stock Jumps 26% as Roth Pushback Turns Short-Seller Hit Into a Rally

T1 Energy Stock Jumps 26% as Roth Pushback Turns Short-Seller Hit Into a Rally

21 May 2026
T1 Energy Inc. shares jumped 26.45% to $8.70 Wednesday after heavy trading and recent volatility. The move follows a short-seller report alleging hidden Chinese ties and tax-credit risks, countered by a Roth Capital analyst’s defense and news of a major institutional stake. T1 reported a $21.4 million net loss but positive adjusted EBITDA and maintained its 2026 production guidance.
Intuit Inc. Expands Credit Karma and QuickBooks AI Push as INTU Stock Slips

Intuit Falls as TurboTax Forecast Cut Weighs on Shares Despite Profit Beat

21 May 2026
Intuit shares fell 13.4% in late trading after the company cut its 2026 TurboTax revenue forecast and announced a 17% reduction in full-time staff, affecting about 3,000 roles globally. The stock closed Wednesday at $383.93 before dropping to $332.48 after hours. Intuit will close its Reno and Woodland Hills offices, with U.S. layoffs effective by July 31.
Go toTop